A recent collaboration between Cytovia Therapeutics and Inserm, the French National Institute of Health and Medical Research, aims to advance new immunotherapies against multiple myeloma based on natural killer cells. Cytovia is developing two distinct therapies for myeloma; one activates and brings these immune cells closer to the cancer cells, the other uses engineered natural killer cells that have a greater ability to fight off cancer. Under the agreement, Cytovia will be able to use specific antibodies…
You must be logged in to read/download the full post.
The post Cytovia, Inserm Partnering on NK-based Immunotherapies for Myeloma appeared first on BioNewsFeeds.